CSTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Castle Biosciences Inc (CSTL) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company shows positive revenue growth and strong analyst support, the recent financial performance, including a significant drop in net income and EPS, combined with neutral technical indicators and lack of strong trading signals, suggests waiting for a clearer entry point.
The MACD histogram is negative (-0.146) and contracting, RSI is at 31.619 (neutral zone), and moving averages are converging, indicating no strong trend. The stock is trading near its support level (S1: 27.209), but no clear bullish signal is present.
Analysts have consistently raised price targets, with the latest target at $50, indicating confidence in the stock's long-term potential.
The company reported strong revenue growth in Q4 2025 and exceeded expectations.
Upcoming presentation at the 2026 Society of Surgical Oncology Annual Meeting could generate positive sentiment.
Net income and EPS have significantly declined YoY, raising concerns about profitability.
Technical indicators do not show a strong bullish trend.
No significant hedge fund or insider trading activity to indicate strong confidence.
In Q4 2025, revenue increased by 0.81% YoY to $87.01 million, but net income dropped by -124.32% YoY to -$2.33 million, and EPS fell by -125.81% YoY to -$0.08. Gross margin improved slightly to 76.33%.
Analysts maintain a positive outlook, with multiple firms raising price targets (ranging from $43 to $50) and maintaining Buy or Overweight ratings. The stock is viewed as having strong long-term potential in the diagnostics sector.
